Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9143039 | 0.88 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11199621 | 0.88 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17541557 | 0.86 | OGA (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL801234 | 0.85 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31023794 | 0.85 | HDAC3 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11329515 | 0.85 | HDAC3 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23032498 | 0.83 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4060160 | 0.82 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19821719 | 0.82 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24469547 | 0.82 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| US-10336775-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2019-07-02 | — | — | US | disclosed |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-3186243-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| WO-2009006413-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005431-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | HDAC3 1212/4885HDAC4 1259/4885HDAC1 652/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | HDAC3 1212/4885HDAC4 1259/4885HDAC1 652/4885 |
| US-20170298082-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | HDAC3 1212/4885HDAC4 1259/4885HDAC1 652/4885 |
| US-10336775-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | HDAC3 1212/4885HDAC4 1259/4885HDAC1 652/4885 |
| US-20090005431-A1 | SUBSTITUTED PYRROLIDINES | CHRM3, CHRM2, CHRM5 | HDAC3 2588/4885HDAC4 3263/4885HDAC1 1996/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | HDAC3 1039/4885HDAC4 901/4885HDAC1 609/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | HDAC3 1212/4885HDAC4 1259/4885HDAC1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.